For Belnacasan datasheet example, Donnem et al. demonstrated that DLL4 positivity was a good prognostic marker in lung adenocarcinoma [27], different from our results. Organ specificity in the evaluation of DLL4 expression of the tumor tissues should be considered. Conclusions In conclusions, cancerous and stromal DLL4 expression may be one of the angiogenesis-related prognostic markers in gastric cancer. Since this protein plays a key role in angiogenesis, future studies are required to determine if antiangiogenic therapy will be useful in DLL4-expressing gastric

cancer. Cancerous and stromal DLL4 expression may be a good target for anti-DLL4 therapy in gastric cancer. References 1. D’souza MA, Singh K, Shrikhande SV: Surgery for gastric cancer: an evidence-based perspective. J Cancer Res Ther 2009, 5:225–231.PubMedCrossRef 2. Rajdev L: Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 2010, 11:14–23.PubMedCrossRef 3. den Dulk M, Verheij M, Cats A, Jansen EP, Hartgrink HH, Van de Velde

CJ: The essentials of locoregional control in the treatment of gastric cancer. Scand J Surg 2006, 95:236–242.PubMed 4. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182–1186.PubMedCrossRef 5. Sato Y: Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol 2003, Luminespib nmr Carteolol HCl 8:200–206.PubMedCrossRef 6. Fernando NH, Hurwitz HI: Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004, 9:11–18.PubMedCrossRef 7. Sledge GW Jr: VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia 2005, 10:319–323.PubMedCrossRef 8. Kerr C: Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol 2005, 6:266.PubMedCrossRef 9. Whisenant J, Bergsland E: Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol 2005, 6:411–421.PubMedCrossRef 10. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, check details Capanu M, Kelsen DP: Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients

With Metastatic Gastroesophageal Adenocarcinoma. J Clin Oncol 2011, 29:868–874.PubMedCrossRef 11. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011, 71:6073–6083.PubMedCrossRef 12. Dufraine J, Funahashi Y, Kitajewski J: Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132–5137.PubMedCrossRef 13. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M, Adams RH: The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124–1135.PubMedCrossRef 14.